---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-030306"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2026-06-26T20:30:19+00:00"
generated_at: "2026-06-26T20:31:34.391036+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# SVP of Finance Sandra Gurrola resigns, effective July 3, 2026

## Summary
- Sandra Gurrola, SVP of Finance, resigned June 22, 2026, effective July 3, 2026.
- Resignation not due to any disagreement with the Company's operations, policies, or practices.
- Gurrola will provide part-time transition assistance (up to 10 hrs/week) through Q2 2026 10-Q filing.
- Company has initiated search for a successor and will use outside support for finance, accounting, and reporting.

## SEC filing metadata
- accession: 0001493152-26-030306
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2026-06-26T20:30:19+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000149315226030306/0001493152-26-030306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000149315226030306/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-030306
- JSON: https://secwatch.observer/filing/0001493152-26-030306.json
- Plain text: https://secwatch.observer/filing/0001493152-26-030306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.